

Contact:

Matthew Lyons
Chief Executive Officer
Phone: 973.316.9900
Email: mlyons@thinkblueslate.com

Blue Slate Highlights Growth Within Orthopedic Device Development Partnership

February 8, 2011, Parsippany, New Jersey – Blue Slate, LLC, a leading investment, development, and management company focused on founding new business opportunities in novel medical technologies, announced today the achievement of several milestones from Extremity Medical, a start-up focused on orthopedic devices targeting the foremost unmet needs specific to treating the distal extremities, including the hand, wrist, foot, and ankle.

Through its management expertise, regulatory knowledge, and ongoing capital investment, Blue Slate has worked with the Extremity Medical management and development teams to bring several novel orthopedic devices to market. Recent successes include:

- 510K clearance from the FDA on the IOFiX Intraosseous Fixation System, designed for performing a variety of procedures in the foot and ankle and providing a completely new approach for delivering compression and stable fixation for fusion of many troublesome joints in the foot (November 2010);
- 510K clearance from the FDA for the company's IOFiX MCP Intraosseous Fixation System for arthrodesis of the metacarpal phalangeal joints in the hand (May 2010), representing the first product for the hand that utilizes intraosseous fixation for fusion of joints in the hand (May 2010);
- FDA clearance for the TrapEZXTM Anatomic Trapezium Prosthesis, the first completely anatomic trapezium bone replacement available in the world (January 2010).

In addition, over the course of the last two years, Blue Slate has also been instrumental in helping Extremity Medical bring to market its HalluX and TarsX products, both designed with the goal of bringing the benefits of intramedullary fixation to the small bones and joints of the foot.

"Blue Slate is extremely excited and proud of the successes and advancements we have been able to make working in conjunction with the highly-skilled management team at Extremity Medical," said Matthew Lyons, chief executive officer of Blue Slate. "When Blue Slate embarked on the development of Extremity Medical, we saw what was an unmet need in the area of small bone and joint reconstruction. By playing an instrumental role in the establishment of Extremity Medical's management and development teams, as well as developing our relationships with key institutions—such as the distinguished Cleveland Clinic—and thought leaders within the orthopedic device community, we have been able to successfully introduce new and novel products into this market and look forward to continued growth and expansion, as well as ultimately improving patient outcomes."

For a detailed overview of recent developmental successes experienced by Blue Slate and Extremity Medical, please visit www.extremitymedical.com.

###

Founded in 2009, Blue Slate is a leading investor in companies focused on the growth of novel medical implants and technologies in the healthcare industry. The company has played an instrumental role in the start-up of several medical and orthopedic device companies, all focused on bringing novel products—from concept to completion—to market.